scPharmaceuticals SCPH 深 沪
等待开盘 04-02 09:30:00 美东时间
5.67
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 5.67
- 总市值 3.04亿
- 52周最高 6.2799
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.94
- 委 比 0.00%
- 总股本 5367.88万
- 历史最高 18.17
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.94
- 每 手 1
- 风险率 1.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MannKind Shares FUROSCIX® Business Updates
FDA approves FUROSCIX for pediatric patients weighing 43kg or above, expanding its use beyond adults with chronic heart failure and kidney disease. Additionally, five new patents for the FUROSCIX ReadyFlow Autoinjector provide extended intellectual property protection through 2040, reinforcing MannKind's position. The autoinjector, currently under FDA review, aims to deliver diuretic doses in seconds, potentially reducing hospital visits and impr...
2025-12-23 13:05
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
MannKind Corporation announced the FDA acceptance of the sNDA for FUROSCIX ReadyFlow Autoinjector, designed to deliver a subcutaneous furosemide dose in under 10 seconds for adult patients with chronic heart failure or kidney disease. If approved, it would offer a faster, more convenient alternative to the current 5-hour on-body infusor, potentially reducing hospital admissions and healthcare costs. The PDUFA target action date is July 26, 2026.
2025-12-01 13:05
Biopharma MannKind's Q3 revenue up 17%
Overview MannKind Q3 2025 rev rises 17% yr/yr to $82.1 mln Adjusted EPS for Q3 2025 increases 45% from last year Company completes acquisition of scPharmaceuticals, boosting revenue growth Outlook Com...
2025-11-05 21:13
MannKind Corporation reports third quarter 2025 revenues of $82.1 million
MannKind Corporation reported third quarter 2025 revenues of $82.1 million, representing a 17% increase compared to the same period in 2024. Year-to-date 2025 revenues reached $237.0 million, up 14% f...
2025-11-05 21:04
scPharmaceuticals Completes Merger and Delists from Nasdaq
The latest update is out from scPharmaceuticals ( ($SCPH) ). On October 7, 2025...
2025-10-07 21:44
scPharmaceuticals Inc. Announces Nasdaq Delisting and SEC Deregistration Following Merger Completion
**scPharmaceuticals Inc. Announces Nasdaq Delisting Following Merger** scPharmaceuticals Inc. has announced that, following the completion of a merger, it will delist its shares from the Nasdaq Global...
2025-10-07 21:19
scPharmaceuticals Issues Promissory Note to MannKind
The latest update is out from scPharmaceuticals ( ($SCPH) ). On September 23, 2...
2025-09-25 16:25
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRY, SCPH, WKHS on Behalf of Shareholders
NEW YORK, Sept. 22, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/o...
2025-09-22 20:46
美股大行评级 | 潜在涨幅163.16%！HIVE Digital Technologies获Roth Capital升目标价至7.5美元，维持"买入"评级
今日重点评级关注：Roth Capital：维持HIVE Digital Technologies"买入"评级，目标价从6美元升至7.5美元；Craig-Hallum：维持Ranpak Hldgs"买入"评级，目标价从8美元升至10美元
2025-08-27 08:32
Craig-Hallum Downgrades scPharmaceuticals to Hold, Announces $6 Price Target
Craig-Hallum analyst Chase Knickerbocker downgrades scPharmaceuticals (NASDAQ:SCPH) from Buy to Hold and announces $6 price target.
2025-08-27 02:01
